Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in …
SR Johnston, DO Constenla, J Moore… - British journal of …, 1998 - nature.com
The purpose of this study was to evaluate in a randomized phase II trial the efficacy and
toxicity of combination biochemotherapy compared with chemotherapy alone in patients with …
toxicity of combination biochemotherapy compared with chemotherapy alone in patients with …
[HTML][HTML] Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and …
E Bajetta, M Del Vecchio, P Nova, A Fusi, A Daponte… - Annals of …, 2006 - Elsevier
Background: The addition of cytokines to chemotherapy (CT) has obtained encouraging but
contradictory results in metastatic melanoma. In this phase III trial, we compared the effects …
contradictory results in metastatic melanoma. In this phase III trial, we compared the effects …
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
MR Middleton, P Lorigan, J Owen, L Ashcroft… - British journal of …, 2000 - nature.com
The purpose of this study was to compare the response rate, overall and 1-year survival in
patients with advanced melanoma treated with a standard therapy, dacarbazine and …
patients with advanced melanoma treated with a standard therapy, dacarbazine and …
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon α2a and tamoxifen in …
MR Sertoli, P Queirolo, E Bajetta… - Melanoma …, 1999 - journals.lww.com
The aim of this study was to evaluate the toxicity and efficacy of a monochemotherapy
regimen of dacarbazine (DTIC), tamoxifen, interferon-α2a and interleukin-2 (IL-2) and two …
regimen of dacarbazine (DTIC), tamoxifen, interferon-α2a and interleukin-2 (IL-2) and two …
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and …
R Hoffmann, I Müller, K Neuber, S Lassmann… - British journal of …, 1998 - nature.com
Combined chemo-/immunotherapy has shown high objective response rates and a
significant though small proportion of long-term complete responders in metastatic …
significant though small proportion of long-term complete responders in metastatic …
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology …
A Hauschild, C Garbe, W Stolz, U Ellwanger… - British journal of …, 2001 - nature.com
In several phase II-trials encouraging tumour responses rates in advanced metastatic
melanoma (stage IV; AJCC-classification) have been reported for the application of …
melanoma (stage IV; AJCC-classification) have been reported for the application of …
[PDF][PDF] Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low dose interleukin-2 for patients with metastatic malignant melanoma
PJ Su, JS Chen, CC Liaw, HK Chang… - … Gung Med J, 2011 - cgmj.cgu.edu.tw
Background: The toxicity and efficacy of biochemotherapy with low-dose interleukin-2 for
patients with metastatic malignant melanoma (MM) were studied. Method: Metastatic chemo …
patients with metastatic malignant melanoma (MM) were studied. Method: Metastatic chemo …
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and …
Purpose Phase II trials with biochemotherapy (BCT) have shown encouraging response
rates in metastatic melanoma, and meta-analyses and one phase III trial have suggested a …
rates in metastatic melanoma, and meta-analyses and one phase III trial have suggested a …
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and …
SS Legha, S Ring, A Bedikian, C Plager, O Eton… - Annals of oncology, 1996 - Elsevier
Background Metastatic melanoma is commonly treated with chemotherapy and/or biological
agents used separately. In this study we have investigated the efficacy of combined …
agents used separately. In this study we have investigated the efficacy of combined …
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-α …
MS Vuoristo, M Hahka-Kemppinen… - Melanoma …, 2005 - journals.lww.com
This randomized phase II study was designed to compare the efficacy and tolerability of
dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with …
dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with …